JapanStake
Pharmaceutical · Fiscal year end Mar 31

KYORIN Pharmaceutical Co., Ltd.

4569

杏林製薬株式会社

FIGI BBG000N1VD714569.T4569 JPCorp. no. 8010001096491

Latest half-year results

First half · fiscal year to 2026-03 · filed 2025-11-13

For the first half of the fiscal year to 2026-03: Revenue ¥58.7 billion (+6.5% YoY), Ordinary income ¥1.6 billion (-22.8% YoY), Net income ¥1.5 billion (+19.0% YoY).

This periodYear on year
Revenue¥58.7bn+6.5%
Ordinary profit¥1.6bn-22.8%
Net profit to owners¥1.5bn+19.0%

From the securities report on EDINET, which states no forecast. History via /v1/companies/4569/earnings-releases.

Financials

Japan GAAP · consolidated · fiscal year to 2026-03-31
Revenue
¥126.3bn
Net income
¥3.4bn
ROE
2.5%
Equity ratio
72.9%
Dividend / share
¥57
Employees
1,982
Revenue · ¥bn
FY2022: ¥105.5bn 106 FY2022FY2023: ¥113.3bn 113 FY2023FY2024: ¥119.5bn 120 FY2024FY2025: ¥130.1bn 130 FY2025FY2026: ¥126.3bn 126 FY2026
Net income · ¥bn
FY2022: ¥3.9bn 3.93 FY2022FY2023: ¥4.7bn 4.72 FY2023FY2024: ¥5.5bn 5.48 FY2024FY2025: ¥9.1bn 9.09 FY2025FY2026: ¥3.4bn 3.45 FY2026
Fiscal yearRevenueNet incomeTotal assetsNet assetsROEEPSOperating CF
2026-03-31¥126.3bn¥3.4bn¥195.5bn¥142.4bn2.5%¥60.03¥6.4bn
2025-03-31¥130.1bn¥9.1bn¥193.6bn¥136.3bn6.8%¥158.17¥3.5bn
2024-03-31¥119.5bn¥5.5bn¥177.6bn¥130.7bn4.3%¥95.41¥1.5bn
2023-03-31¥113.3bn¥4.7bn¥176.0bn¥125.5bn3.8%¥82.44¥2.0bn
2022-03-31¥105.5bn¥3.9bn¥171.9bn¥124.5bn3.2%¥68.62¥6.3bn

Indicators

Computed by us from filings · fiscal year to 2026-03-31
MetricValuePercentile among listed companies
ROE, %2.512.8
Ordinary margin0.031925.7
Equity ratio, %72.979.6
Revenue growth-0.029415.8
Net income growth-0.620511.2
Operating cash flow / assets0.032629.5
Policy-uncertainty measure0.78 Share of the report's text discussing policy-related uncertainty, by policy area. Proprietary text method.
Regulation 1
Ownership activity 0 filer(s) stated they may make proposals in 365 days; 2 new 5% holder(s) in 180 days; net stake change +1.34pt in 90 days; 6.7% held by other listed companies.

Results wording balance: -0.25. Proprietary text method; it describes the wording only and does not interpret context.

Interest example: if all ¥23.3bn of reported debt repriced by 50 basis points, a year's interest would rise by ¥117m, 1.8% of operating cash flow. Our arithmetic only, not a forecast: fixed-rate debt and hedges are ignored.

Via /v1/companies/4569/indicators. Descriptive figures, not a rating and not investment advice.

From other filings

As the company states them
Internal control, 2026-06-18: see filing 上記の評価の結果、当事業年度末日時点において、当社の財務報告に係る内部統制は有効であると判断しました。 Filing

Segments, votes and tender offers

Stated in EDINET filings
Latest voting result: 2026-06-19 · 取締役6名選任の件 · passed. /v1/companies/4569/voting

Ownership changes

All companies →
  • 2026-10-27
    Increase+1.34pt

    Kopernik Global Investers, LLC raised holdings in KYORIN Pharmaceutical Co., Ltd. (4569) to 10.09% from 8.75%.

    01020304050
    S100Z9S3Filer profileOriginal filing (PDF, Japanese)
  • 2026-10-27
    Threshold

    Holdings of Kopernik Global Investers, LLC in KYORIN Pharmaceutical Co., Ltd. (4569) moved above 10% (8.75% -> 10.09%).

    01020304050
    S100Z9S3Filer profileOriginal filing (PDF, Japanese)
  • 2026-08-05
    New 5% stake

    individual filer disclosed a 6.19% stake in KYORIN Pharmaceutical Co., Ltd. (4569), crossing the 5% reporting threshold.

    01020304050
    S100YTPPOriginal filing (PDF, Japanese)
  • 2026-08-05
    New 5% stake

    individual filer disclosed a 5.91% stake in KYORIN Pharmaceutical Co., Ltd. (4569), crossing the 5% reporting threshold.

    01020304050
    S100YTRCOriginal filing (PDF, Japanese)
  • 2026-08-05
    Below 5%−6.02pt

    individual filer cut holdings in KYORIN Pharmaceutical Co., Ltd. (4569) to 0.21% from 6.23%, below the 5% threshold.

    01020304050
    S100YTSWOriginal filing (PDF, Japanese)
  • 2026-05-11
    Increase+1.11pt

    Kopernik Global Investers, LLC raised holdings in KYORIN Pharmaceutical Co., Ltd. (4569) to 8.75% from 7.64%.

    01020304050
    S100Y2MHFiler profileOriginal filing (PDF, Japanese)
  • 2025-12-22
    Decrease−1.11pt

    Kopernik Global Investers, LLC reduced holdings in KYORIN Pharmaceutical Co., Ltd. (4569) to 7.64% from 8.75%.

    01020304050
    S100XBT1Filer profileOriginal filing (PDF, Japanese)
  • 2025-08-05
    Increase+1.35pt

    individual filer raised holdings in KYORIN Pharmaceutical Co., Ltd. (4569) to 13.47% from 12.12%.

    01020304050
    S100WF9IOriginal filing (PDF, Japanese)
  • 2025-06-06
    Increase+1.51pt

    Kopernik Global Investers, LLC raised holdings in KYORIN Pharmaceutical Co., Ltd. (4569) to 8.75% from 7.24%.

    01020304050
    S100VW7HFiler profileOriginal filing (PDF, Japanese)
  • 2024-07-22
    Increase+1.01pt

    Kopernik Global Investers, LLC raised holdings in KYORIN Pharmaceutical Co., Ltd. (4569) to 7.24% from 6.23%.

    01020304050
    S100U30TFiler profileOriginal filing (PDF, Japanese)

Trades by 5% holders

From the 60-day trade tables in 5% reports
¥1,142¥1,711¥2,279 2019-02-062026-07-31 2026-07-31 · bought 1,950,000 @ ¥1,142 · individual filer2026-07-31 · bought 1,950,000 @ ¥1,142 · individual filer2025-08-01 · bought 235,000 @ ¥1,543 · individual filer2024-02-08 · sold 1,110,200 @ ¥1,758 · individual filer2024-02-08 · sold 1,807,400 @ ¥1,758 · individual filer2024-02-08 · bought 100,000 @ ¥1,758 · individual filer2024-02-08 · bought 2,817,600 @ ¥1,758 · individual filer2019-02-06 · sold 1,000,000 @ ¥2,279 · individual filer
Bought SoldHover a dot for the trade
HolderPeriodNet sharesNet % of sharesAvg. filed priceRange
Kopernik Global Investers, LLC2026-08-19 – 2026-10-15+6,000+0.01pt——
individual filer2026-07-31 – 2026-07-31-1,950,000−3.25pt——
individual filer2026-07-31 – 2026-07-31-1,950,000−3.25pt——
individual filer2026-07-31 – 2026-07-31+1,950,000+3.25pt¥1,142¥1,142–1,142
individual filer2026-07-31 – 2026-07-31+1,950,000+3.25pt¥1,142¥1,142–1,142
individual filer2024-02-08 – 2025-08-01+335,000+0.54pt¥1,607.18¥1,543–1,758
individual filer2019-02-06 – 2024-02-08-2,110,200−3.27pt¥2,004.9¥1,758–2,279
individual filer2024-02-08 – 2024-02-08-1,807,400−2.80pt¥1,758¥1,758–1,758
individual filer2024-02-08 – 2024-02-08+2,817,600+4.36pt¥1,758¥1,758–1,758

Net shares and the average are our calculations. Prices are filed prices as stated by the filer, mostly for off-market trades; they are not market prices. Stock lending, custody transfers and option exercises are excluded from net shares. Every row via /v1/companies/4569/trades.

5% filings

Large shareholding reports on 4569
FiledFilerStakeChangeStated purpose
2026-10-27Kopernik Global Investers, LLC10.09%+1.34ptpure investment
2026-08-05individual filer6.19%——
2026-08-05individual filer5.91%——
2026-08-05individual filer0.21%−6.02pt—
2026-05-11Kopernik Global Investers, LLC8.75%+1.11ptpure investment
2025-12-22Kopernik Global Investers, LLC7.64%−1.11ptpure investment
2025-08-05individual filer13.47%+1.35pt—
2025-06-06Kopernik Global Investers, LLC8.75%+1.51ptpure investment
2024-07-22Kopernik Global Investers, LLC7.24%+1.01ptpure investment
2024-02-16individual filer12.12%+1.73pt—

Cross-shareholdings

From the annual report's status of shareholdings
Listed strategic holdings
10 issues
Book value
¥17.5bn
Sold in the year
¥762m 1 issues
Bought in the year
— — issues
Mutual, both reports
8
Held by listed cos.
10
HoldsBook valueShares vs. prior yearMutual
ONO PHARMACEUTICAL CO., LTD. 4528¥4,549m0.0%both reports
KAKEN PHARMACEUTIAL CO., LTD. 4521¥3,529m0.0%both reports
AIN HOLDINGS INC. 9627¥2,250m0.0%no
KISSEI PHARMACEUTICAL CO.,LTD. 4547¥2,111m0.0%both reports
TOHO HOLDINGS CO.,LTD. 8129¥1,785m0.0%both reports
MEDIPAL HOLDINGS CORPORATION 7459¥1,267m0.0%both reports
Alfresa Holdings Corporation 2784¥807m0.0%both reports
Mizuho Financial Group, Inc. 8411¥696m0.0%stated
SUZUKEN CO.,LTD. 9987¥348m0.0%both reports
株式会社ほくやく・竹山ホールディングス¥114m0.0%stated

Held by: KAKEN PHARMACEUTIAL CO., LTD. 4521, ONO PHARMACEUTICAL CO., LTD. 4528, KISSEI PHARMACEUTICAL CO.,LTD. 4547, TOHO HOLDINGS CO.,LTD. 8129, SUZUKEN CO.,LTD. 9987, MEDIPAL HOLDINGS CORPORATION 7459, Alfresa Holdings Corporation 2784, TSUMUGU Holdings, Inc. 3055, Daito Pharmaceutical Co., Ltd. 4577, VITAL KSK HOLDINGS,INC. 3151, VITAL KSK HOLDINGS,INC. 3151

Purposes, all holdings and mutual flags via /v1/companies/4569/cross-holdings. Share changes include stock splits.

Major shareholders

As of fiscal year end 2026-03-31
ShareholderSharesRatio
日本マスタートラスト信託銀行株式会社（信託口）6,053,00010.41%
株式会社マイカム5,178,0008.90%
株式会社ルキウス2,817,0004.84%
株式会社日本カストディ銀行（信託口）2,207,0003.79%
キョーリン製薬グループ持株会2,090,0003.59%
individual holder1,995,0003.43%
株式会社バンリーナ1,950,0003.35%
株式会社アーチァンズ1,950,0003.35%
株式会社ルーチェス1,760,0003.02%
科研製薬株式会社1,602,0002.75%

U.S. funds holding 4569

SEC Form N-PORT, reports to 2026-07-31

54 U.S. funds held 5,803,529 shares worth $41.7m.

FundSharesValue% of fundAs of
Kopernik Global All-Cap Fund
ADVISORS' INNER CIRCLE FUND II
2,121,500$15.2m0.470%2026-07-31
iShares Core MSCI EAFE ETF
iShares Trust
585,600$4.2m0.002%2026-07-31
VANGUARD TOTAL INTERNATIONAL STOCK INDEX FUND
VANGUARD STAR FUNDS
569,808$4.1m0.001%2026-07-31
VANGUARD DEVELOPED MARKETS INDEX FUND
VANGUARD TAX-MANAGED FUNDS
383,606$2.7m0.001%2026-06-30
THE JAPANESE SMALL COMPANY SERIES
DFA INVESTMENT TRUST CO
204,248$1.5m0.036%2026-07-31

Up to 25 funds per stock via the API.

Get this as JSON

GET /v1/companies/4569
GET /v1/companies/4569/financials
GET /v1/companies/4569/details
GET /v1/companies/4569/segments
GET /v1/companies/4569/voting
GET /v1/companies/4569/tender-offers
GET /v1/companies/4569/indicators
GET /v1/companies/4569/earnings-releases
GET /v1/events?ticker=4569
GET /v1/companies/4569/trades         
GET /v1/companies/4569/cross-holdings 
GET /v1/companies/4569/brief

Plans from $9 a month · Documentation